Lablytica Life Science
Lablytica Life Science is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
Sponsor Cinclus Pharma Holding AB (publ)
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of 2 doses of vipoglanstat in patients with moderate to severe endometriosis-related pain – the NOVA trial
Sponsor Gesynta Pharma AB
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer
Sponsor OncoZenge AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of golexanolone in subjects with primary biliary cholangitis, fatigue, and cognitive dysfunction.
Sponsor Umecrine Cognition AB
- Start (EU)
- Latest update
- Estimated end
A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
Sponsor Affibody AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis.
Sponsor Vicore Pharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy
Sponsor Integrative Research Laboratories Sweden AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Interventional, randomised, double-blind, placebo-controlled, multiple-ascending-dose, first-in- human trial to determine the safety and tolerability of the MEK1/2 inhibitor EDV2209 in patients with Subarachnoid Haemorrhage – SAH
Sponsor Edvince AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Lablytica Life Science?
The 2026-10-09 snapshot links Lablytica Life Science to 8 distinct CTIS trials. Recorded services include Laboratory services, Pharmacokinetic bioanalysis, PK analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lablytica Life Science?
The most frequently recorded therapeutic areas are Gastroenterology, Pain Medicine, Solid Tumor Oncology, Gynecology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lablytica Life Science conducted?
The linked trials record locations in 15 countries, including Germany, Poland, Bulgaria, Hungary, Italy. These are trial locations, not confirmed office locations or countries where Lablytica Life Science delivered services.
What can this page tell me about Lablytica Life Science's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Lablytica Life Science. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lablytica Life Science AB